Skip to content

To compare the two drugs sugammadex and neostigmine in reversing the patient , who is paralysed by vecuronium

Comparison of sugammadex and neostigmine for reversal of vecuronium induced neuromuscular blockade in elderly patients - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/071849
Enrollment
96
Registered
2024-08-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 4- Measurement and Monitoring

Interventions

Intervention1: Neostigmine, sugammadex: To compare sugammadex and neostigmine in terms of quality of reversal of neuromuscular blockade and post operative curarization in elderly patients. Interventio

Sponsors

Institute of medical sciences, SUM hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing elective surgeries of age greater than 60 years and patients of ASA 1 and ASA 2

Exclusion criteria

Exclusion criteria: Patients who are not willing to give consent for the study, patient known allergic to narcotics, muscle relaxants, or other medication used during general anaesthesia, patients with anticipation of difficult airway, patients on drugs which are known to interact with neuromuscular blocking drugs, patients with significant renal dysfunction, patients who are known or suspected neuromuscular disorders

Design outcomes

Primary

MeasureTime frame
To determine the time taken from start of study drug injection to train of four 0.9 ratioTimepoint: Check train of four count every twenty minutes for one hour

Secondary

MeasureTime frame
Look for other adverse effects of the drug such as nausea, vomiting, altered tasteTimepoint: Check for every twenty minutes for one hour

Countries

India

Contacts

Public ContactDr GUNDA RAVI SHANKER REDDY

Institute of medical sciences, SUM hospital

drswastika81@yahoo.com9861628628

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026